Summary
Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Actinium Pharmaceuticals Inc. (ATNM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Actinium Pharmaceuticals Inc. ever had a stock split?
Actinium Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sandesh C. Seth CEO | AMEX Exchange | 00507W107 CUSIP |
| US Country | 31 Employees | - Last Dividend | 11 Aug 2020 Last Split | - IPO Date |
Overview
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of targeted radiotherapies. These therapies aim to deliver precise, cancer-killing radiation to patients with high unmet medical needs, particularly those who have not responded well to traditional treatments. The company's mission is to advance the treatment landscape for these patients through its innovative radioimmunotherapy technology. Actinium Pharmaceuticals, based in New York, New York, is leading the way in this exciting field by focusing on a range of radioactive isotopes and collaborating with prominent industry and academic partners.
Products and Services
Actinium Pharmaceuticals, Inc. leverages its expertise in radioimmunotherapy to create a diverse portfolio of product candidates and development programs:
- Iomab-B (I-131 apamistamab): A leading product candidate currently in a pivotal Phase III clinical trial. It targets relapsed and refractory acute myeloid leukemia (AML) patients, making them eligible for bone marrow transplant. This innovative therapy combines the precision of targeted antibodies with the potent cancer-killing capabilities of radiation.
- CD19-Targeted CAR T-Cell Therapy Collaboration with Memorial Sloan Kettering Cancer Center: Actinium is involved in a Phase I study focusing on the synergistic potential of combining CD19-targeted CAR T-cell therapy with its targeted radiotherapy technology, aiming to enhance the efficacy of CAR T-cell therapy in difficult-to-treat cancers.
- Actinium-225-Based Therapies: The company is exploring the therapeutic potential of Actinium-225, an alpha-emitting isotope known for its high-energy output and short range, making it ideal for targeting cancer cells while minimizing damage to surrounding healthy tissue. This includes Iomab-ACT for conditioning in gene and cell therapy applications.
- Actimab-A Programs: These include a series of combinations like Actimab-A (CD33) with CLAG-M, Venetoclax, and Venetoclax with HMA, designed to target CD33-expressing AML cells. These combinations are being tested in various stages of clinical development, focusing on improving treatment outcomes for AML patients.
- Collaboration with Astellas Pharma, Inc.: This partnership aims to develop theranostic (therapeutic and diagnostic) approaches for solid tumor indications, marrying Actinium’s radiotherapy expertise with Astellas’s vast experience in oncology.
- Partnership with EpicentRx, Inc.: Focused on developing a novel CD47-SIRPa immunotherapy targeted radiotherapy. This collaboration seeks to harness the "don't eat me" signal exploited by cancer cells to evade destruction by the immune system, by targeting it with radiotherapy to potentially enhance patient outcomes.
- Licensing Agreement with Immedica Pharma: Actinium has licensed the rights to commercialize Iomab-B to Immedica Pharma, a strategic step towards bringing this potentially life-saving therapy to patients worldwide.
Contact Information
